FDA’s New Leadership May Be More Amenable To Expanded Access Programs
This article was originally published in The Pink Sheet Daily
Executive Summary
Patient activists say shift in Iplex case shows that the agency may begin to allow more compassionate use for products in development.
You may also be interested in...
Hamburg, Sharfstein Appointments To FDA Shift Focus To Future Plans Of Career Officials
President Obama praises Hamburg's "reputation of integrity" and record of public health acheivements in making nominations March 14.
FDA’s Compassionate Use Policy: Is Tysabri A Precedent Or A Special Case?
When FDA stepped in and helped prominent trial lawyer and Democratic fundraiser Fred Baron get access to Tysabri for off-label treatment of his multiple myeloma, it raised questions about whether the agency had adopted a new policy
Expanded Access Program For Insmed’s Iplex Shows Power Of Patient Advocates At FDA
Lou Gehrig’s patients who appealed to the agency early will get access to drug; others enter a lottery system as part of a clinical trial.